Autolus Therapeutics

Developing next-generation programmed T cell therapies

Autolus is developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Status
NASDAQ: AUTL
Year of Investment
2021
Strategy
Life Sciences
Location
White City, London